Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 16.78
(0.78%)
CNY 16.78
(0.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.19 Million CNY | 98.89% |
| 2022 | -378.82 Million CNY | 31.59% |
| 2021 | -553.71 Million CNY | 43.46% |
| 2020 | -979.36 Million CNY | -764.96% |
| 2019 | -113.22 Million CNY | -740.49% |
| 2018 | -13.47 Million CNY | -115.05% |
| 2017 | 89.53 Million CNY | -65.14% |
| 2016 | 256.82 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 107.23 Million CNY | 2654.42% |
| 2024 Q3 | 704.33 Million CNY | 35.64% |
| 2024 Q2 | 519.27 Million CNY | 384.24% |
| 2023 Q3 | -245.94 Million CNY | -57.42% |
| 2023 Q2 | -156.23 Million CNY | 39.4% |
| 2023 Q1 | -257.8 Million CNY | 31.94% |
| 2023 FY | -4.19 Million CNY | 98.89% |
| 2023 Q4 | -4.19 Million CNY | 98.29% |
| 2022 Q4 | -378.82 Million CNY | -17.59% |
| 2022 Q3 | -322.15 Million CNY | 21.82% |
| 2022 Q2 | -412.04 Million CNY | 16.4% |
| 2022 FY | -378.82 Million CNY | 31.59% |
| 2022 Q1 | -492.89 Million CNY | 10.98% |
| 2021 Q4 | -553.71 Million CNY | -1.65% |
| 2021 Q3 | -544.73 Million CNY | 21.72% |
| 2021 Q2 | -695.84 Million CNY | -21.41% |
| 2021 FY | -553.71 Million CNY | 43.46% |
| 2021 Q1 | -573.14 Million CNY | 41.48% |
| 2020 FY | -979.36 Million CNY | -764.96% |
| 2020 Q4 | -979.36 Million CNY | -494.68% |
| 2020 Q3 | -164.68 Million CNY | -11.19% |
| 2020 Q2 | -148.11 Million CNY | -211.17% |
| 2020 Q1 | 133.22 Million CNY | 217.66% |
| 2019 Q2 | -48.54 Million CNY | 0.0% |
| 2019 FY | -113.22 Million CNY | -740.49% |
| 2019 Q4 | -113.22 Million CNY | 0.0% |
| 2018 FY | -13.47 Million CNY | -115.05% |
| 2017 FY | 89.53 Million CNY | -65.14% |
| 2016 FY | 256.82 Million CNY | 0.0% |